CJC-1295 With DAC

CJC-1295 with DAC for Sale – Research Use Only

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic, long-acting Growth Hormone-Releasing Hormone (GHRH) analog developed for laboratory research. The peptide is derived from the first 29 amino acids of endogenous GHRH and incorporates a Drug Affinity Complex (DAC) that enables albumin binding, significantly extending its half-life compared to unmodified GHRH analogs.

Researchers investigate CJC-1295 with DAC for its role in somatotropic axis signaling, growth hormone secretion dynamics, endocrine pathways, peptide pharmacokinetics, and IGF-1 signaling. Its extended activity profile makes it a valuable investigational compound for long-duration preclinical studies.

Research Use Only: This product is intended exclusively for laboratory research. It is not approved for human consumption, veterinary use, therapeutic applications, or diagnostic procedures.

Key Features

• 99% purity verified by independent HPLC testing
• Certificate of Analysis (COA) available for every batch
• Long-acting GHRH analog with Drug Affinity Complex (DAC)
• Extended albumin-binding pharmacokinetic profile
• Ideal for endocrine and peptide pharmacology research
• Research Use Only (RUO)

Chemical & Molecular Properties

Compound	CJC-1295 with DAC
CAS Number	446262-90-4
PubChem CID	56841945
Molecular Formula	C₁₆₅H₂₆₉N₄₇O₄₆
Molecular Weight	3647.2 g/mol
Purity	99% (HPLC Verified)
Classification	Synthetic GHRH Analog with Drug Affinity Complex (DAC)
Half-Life	Approximately 6–8 Days (Preclinical Models)
Solubility	Bacteriostatic Water, Sterile Water, or Dilute Acetic Acid
Research Classification	Research Use Only (RUO)

Mechanism Under Investigation

Preclinical studies suggest that CJC-1295 with DAC functions as a GHRH receptor agonist, activating the adenylyl cyclase-cAMP-PKA signaling pathway associated with pulsatile growth hormone secretion. The Drug Affinity Complex binds to circulating serum albumin, reducing enzymatic degradation and extending peptide circulation in laboratory models.

Research also investigates downstream effects involving IGF-1 signaling, endocrine regulation, and pharmacokinetic behavior. These findings are derived exclusively from laboratory and preclinical research and have not been validated for therapeutic use.

Potential Research Applications

• Growth hormone secretion research
• Somatotropic axis investigations
• IGF-1 pathway research
• Endocrine signaling studies
• Peptide pharmacokinetic modeling
• Albumin-binding peptide research
• Metabolic regulation investigations

Storage Recommendations

• Store lyophilized powder at −20°C.
• Protect from moisture, heat, and direct light.
• After reconstitution, refrigerate at 2–8°C.
• Avoid repeated freeze-thaw cycles.
• Keep in the original sealed container until laboratory use.

Quality Assurance

PureRawz manufactures research peptides under strict quality standards. Every batch of CJC-1295 with DAC undergoes independent analytical testing with HPLC verification, and each lot includes a Certificate of Analysis (COA) confirming purity and identity.

Frequently Asked Questions

What is CJC-1295 with DAC researched for?

Researchers study CJC-1295 with DAC for growth hormone signaling, IGF-1 pathway activity, endocrine regulation, peptide pharmacokinetics, and sustained GHRH receptor activation.

What does the DAC modification do?

The Drug Affinity Complex (DAC) enables albumin binding, significantly extending the peptide’s circulation time in preclinical research models.

Is CJC-1295 with DAC FDA approved?

No. CJC-1295 with DAC is an investigational research peptide and has not been approved by the FDA for human or veterinary use.

Does every batch include a COA?

Yes. Every production batch is independently tested and includes a Certificate of Analysis (COA).

Important Disclaimer

Research Use Only: CJC-1295 with DAC is supplied exclusively for laboratory and scientific research. This product is not intended for human consumption, veterinary use, diagnosis, treatment, cure, or prevention of any disease. Researchers are responsible for ensuring compliance with all applicable institutional and regulatory requirements.